In short
Clinical trials are studying Ly3556050 in adults with diabetic peripheral neuropathic pain. These studies aim to see whether it can reduce pain better than placebo and measure changes in pain scores over time. The trial data shown here focuses on adults with diabetic peripheral neuropathy in a Phase 2 study.
Key points
- Clinical trials of Ly3556050 are studying adults with diabetic peripheral neuropathic pain. The main trial listed here is a Phase 2 interventional study with 410 planned participants and a completed status. Researchers compared Ly3556050 with placebo to see whether at least one dose could reduce pain better than placebo. The main endpoint was the change in Average Pain Intensity Numeric Rating Scale, which tracks pain score changes from the start of the study. This trial focuses on pain relief in adults with diabetic peripheral neuropathy.
Trial overview
This clinical trial studied Ly3556050 in adults with diabetic peripheral neuropathic pain. The study was interventional, which means researchers gave a study treatment and then measured the results.
Who the trial studies
The target population was adult participants with diabetic peripheral neuropathy, a form of nerve damage linked to diabetes. The study title also describes the condition as diabetic peripheral neuropathic pain, which is pain caused by that nerve damage.
Treatments and comparison
The trial compared Ly3556050 with placebo, which is a look-alike treatment without the active study drug. The intervention list shows Ly3556050 and placebo to match Ly3556050, so the study was designed to see whether Ly3556050 performed better than placebo for pain relief.
Trial phase and design
This was a Phase 2 study. Phase 2 trials usually look more closely at whether a treatment may work while continuing to collect safety information, although the source here mainly states the phase and the study goal.
The trial was planned as a study with 410 participants. That size suggests the researchers wanted enough people to compare pain results between treatment groups.
Main outcome measured
The primary outcome was the Mean Change from Baseline for Average Pain Intensity Numeric Rating Scale (API-NRS). In simple terms, this means the study measured how much the pain score changed from the start of the trial to later time points. The brief study summary says the goal was to show that at least one dose of Ly3556050 was better than placebo in pain intensity.
What completed means
The trial status is completed. This means the study has finished and the planned data collection is done.